Bionano Genomics, Inc. BNGOW 深 滬
已收盤 08-17 16:00:00 美东时间
0.0036
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0036
- 總市值 100.37万
- 52周最高 0.604
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0019
- 委 比 0.00%
- 總股本 2.79亿
- 歷史最高 11.82
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.0019
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bionano Genomics Publishes Study On Application Of Optical Genome Mapping To Trace Genomic Alterations Introduced By Different Gene Editing Technologies
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to detect genomic
02-04 21:07
Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
Bionano Genomics reported preliminary Q4 and FY2025 financial results. Total Q4 revenue is expected to be $7.8M-$8.0M, a 2%-4% YoY decrease. FY2025 revenue is projected at $28.4M-$28.6M, down 7%-8% YoY. They sold 30,171 nanochannel array flowcells and installed 32 new OGM systems in FY2025. Notably, they achieved reimbursement progress with two new CPT codes, expanded clinical research evidence, and upgraded their software platforms. As of Dec 31...
01-12 13:00
Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
Bionano Genomics participated in the 2025 AMP Annual Meeting, showcasing Optical Genome Mapping (OGM) technology for enhanced structural variant (SV) detection._presentations highlighted OGM's utility across inherited diseases, reproductive disorders, hematological malignancies, and solid tumors. Thirteen studies demonstrated OGM's ability to detect novel and clinically relevant SVs, often complementing traditional methods. Researchers also prese...
2025-12-11 13:00
Bionano Laboratories Gains 47% CMS Reimbursement Increase For OGM Blood-Cancer Test Code 81195 In 2026
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical
2025-12-03 21:06
Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies
Bionano Laboratories announced a 47% increase in the CMS fee schedule for CPT code 81195, from $1263.53 to $1853.22, effective January 1, 2026. This code covers OGM-based cytogenomic analysis for hematologic malignancies. The increase follows a CDLT committee vote in favor of a crosswalk to a higher-paying code. Bionano expects the higher reimbursement to facilitate wider adoption of its OGM-based LDTs and enhance awareness of OGM's utility in on...
2025-12-03 13:00
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Lowers Price Target to $7
HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $11 to $7.
2025-11-24 20:45
Bionano jumps 6% on Q3 revenue beat, 2025 guidance range
Bionano Genomics (BNGO) is up ~6% in after-hours trading Thursday after reporting Q3 financial results that beat on revenue and reiterating full-year revenue guidance that includes the consensus. Full...
2025-11-14 06:51
Bionano Genomics Affirms FY2025 Sales Guidance of $26.000M-$30.000M vs $28.136M Est
Bionano Genomics (NASDAQ:BNGO) affirms FY2025 sales outlook from $26.000 million-$30.000 million to $26.000 million-$30.000 million vs $28.136 million estimate.
2025-11-14 06:16
Bionano Genomics Q3 Sales $7.367M Beat $6.871M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly sales of $7.367 million which beat the analyst consensus estimate of $6.871 million by 7.22 percent. This is a 21.31 percent increase over sales of $6.073 million the
2025-11-14 05:02
Bionano Genomics Publishes Study Demonstrating That Optical Genome Mapping Can Overcome Key Limitations Of Targeted RNA-Sequencing Panels In Detecting Therapeutically Relevant Gene Rearrangements In Acute Leukemia
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address key limitations of
2025-11-06 21:28
